Bob Salim

766 total citations
8 papers, 41 citations indexed

About

Bob Salim is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Rheumatology. According to data from OpenAlex, Bob Salim has authored 8 papers receiving a total of 41 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 4 papers in Rheumatology. Recurrent topics in Bob Salim's work include HER2/EGFR in Cancer Research (3 papers), Rheumatoid Arthritis Research and Therapies (3 papers) and Advanced Breast Cancer Therapies (2 papers). Bob Salim is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Rheumatoid Arthritis Research and Therapies (3 papers) and Advanced Breast Cancer Therapies (2 papers). Bob Salim collaborates with scholars based in United States, Canada and Spain. Bob Salim's co-authors include George Reed, Joel M. Kremer, Philip J. Mease, David H. Collier, Dimitrios A. Pappas, Sabrina Rebello, Chitra Karki, Vishvas Garg, Scott Stryker and Mei Liu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Bob Salim

7 papers receiving 41 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bob Salim United States	4	28	13	13	9	7	8	41
Khushleen Jaggi United States	2	11 0.4×	15 1.2×	19 1.5×	8 0.9×	16 2.3×	3	50
L Hebert United States	4	31 1.1×	5 0.4×	19 1.5×	7 0.8×	4 0.6×	7	60
Marek Dudziński Poland	4	28 1.0×	19 1.5×	7 0.5×	6 0.7×	21 3.0×	11	50
Teresa Ruíz Spain	4	26 0.9×	15 1.2×	19 1.5×	5 0.6×	22 3.1×	4	51
Tim Röhnisch Germany	3	9 0.3×	11 0.8×	7 0.5×	7 0.8×	4 0.6×	3	49
C. Moriano Spain	5	39 1.4×	13 1.0×	6 0.5×	3 0.3×	35 5.0×	18	59
Maddalena Marconato Germany	4	6 0.2×	6 0.5×	17 1.3×	4 0.4×	7 1.0×	8	32
T. Cardillo United States	5	30 1.1×	10 0.8×	7 0.5×	17 1.9×		7	55
Ming Lin Australia	4	8 0.3×	12 0.9×	4 0.3×	14 1.6×	3 0.4×	9	32
Yervand Hakobyan Armenia	4	47 1.7×	32 2.5×	9 0.7×	16 1.8×	1 0.1×	13	66

Countries citing papers authored by Bob Salim

Since Specialization

Citations

This map shows the geographic impact of Bob Salim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bob Salim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bob Salim more than expected).

Fields of papers citing papers by Bob Salim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bob Salim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bob Salim. The network helps show where Bob Salim may publish in the future.

Co-authorship network of co-authors of Bob Salim

This figure shows the co-authorship network connecting the top 25 collaborators of Bob Salim. A scholar is included among the top collaborators of Bob Salim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bob Salim. Bob Salim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Escrivá-de-Romaní, Santiago, Juan Miguel Cejalvo, Emilio Alba, et al.. (2025). Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study. The Lancet Oncology. 26(6). 745–758. 2 indexed citations

Montero, Alberto J., Kari B. Wisinski, Bruno Fang, et al.. (2025). Abstract PS8-09: Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study. Clinical Cancer Research. 31(12_Supplement). PS8–9.

Escrivá-de-Romaní, Santiago, Juan Miguel Cejalvo, Emilio Alba, et al.. (2024). Abstract LBO1-04: Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC). Cancer Research. 84(9_Supplement). LBO1–4. 3 indexed citations

Mease, Philip J., Scott Stryker, Mei Liu, et al.. (2021). Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry. Arthritis Research & Therapy. 23(1). 236–236. 11 indexed citations

Knapp, Keith, et al.. (2021). Treatment Patterns, Disease Burden, and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Real-World, Electronic Health Record-Based Study of Patients in Clinical Practice. Rheumatology and Therapy. 8(1). 529–539. 4 indexed citations

Yu, Evan Y., Steven P. Fling, Bob Salim, et al.. (2019). A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14).. Journal of Clinical Oncology. 37(15_suppl). TPS4586–TPS4586. 2 indexed citations

Boytsov, Natalie, C. Gaich, Xiang Zhang, et al.. (2018). Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort Study. Rheumatology and Therapy. 5(1). 215–229. 4 indexed citations

Pappas, Dimitrios A., Joel M. Kremer, Jenny Griffith, et al.. (2017). Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry. Rheumatology and Therapy. 4(2). 375–389. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact